Efficacy and Safety of FTY720 in Patients With Relapsing Multiple Sclerosis (MS)

A 6-month, Double-blind, Randomized, Placebo-controlled, Parallel-group, Multicenter Study Comparing Efficacy and Safety of FTY720 0.5 mg and 1.25 mg Administered Orally Once Daily in Patients With Relapsing Multiple Sclerosis

To provide efficacy and safety data of two doses (0.5 mg and 1.25 mg) of FTY720 in Japanese patients with relapsing multiple sclerosis (MS)

Inclusion Criteria:

• Male and female patients aged 18-60
• Patients with a diagnosis of multiple sclerosis

Exclusion Criteria:

• Patients with a history or presence of chronic disease of the immune system other than MS
• Patients with a history or presence of malignancy, pulmonary or heart disease, etc.
• Pregnant or nursing (lactating) women

Other protocol-defined inclusion/exclusion criteria may apply